ArticleEJHaem2026
Prevalence of Low Bone Mineral Density Increases With Age in Sickle Cell Disease.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Skeletal complications are common in sickle cell disease (SCD). We previously showed that the prevalence of low areal bone mineral density (aBMD) increased with age in a pediatric SCD cohort, even after adjusting for short stature. Data on age-related aBMD trends in young adults is lacking. Methods: Using retrospective data from the Sickle Cell Clinical Research and Intervention Program (SCCRIP), we converted lumbar spine (LS) and total body (TB) aBMD from 713 SCCRIP participants (49.2% females, ages 6-24 years) to age-, sex-, ancestry-, and height-adjusted Results: Low TB bone density prevalence rates increased with age: 29.5% in children (6-< 12 years), 36.7% in adolescents (12-< 18 years), and 42.2% in young adults (18-24 years). LS aBMD followed a similar age-related trend. Multivariable analysis revealed older age (OR 1.10, 95% CI 1.06-1.16), lower hemoglobin (OR 0.833, 95% CI 0.740-0.936), and higher eGFR (OR 1.01, 95% CI 1.00-1.02) as independent predictors for low TB BMD. Conclusion: These findings highlight the progressive decline of aBMD in SCD and underscore the need for early screening to mitigate morbidity due to SCD-related skeletal complications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.